

TAK-003 for Travelers: Insights from Japanese Travel Medicine Providers

Descriptive study



May 31 to June 30, 2024




TAK-003 (Qdenga®)



Dengue



Opinions and decision-support information among travel medicine providers is limited



Surveyed 154 travel medicine providers in Japan for opinions regarding Qdenga vaccine that has not yet been approved in the country



High willingness to accept TAK-003:



Long-term travel



Short-term travel



High recommendations for TAK-003:



Long-term travel




Short-term travel



Main concerns for non-recommendation:



Efficacy



Antibody-dependent enhancement risk



Adverse reactions



Need for decision-support in dengue vaccine recommendations

- Scientific evidence on safety and efficacy
- Data on dengue-endemic regions
- International vaccination guidelines

Atsuko Fukunishi, Masaki Machida, Shinji Fukushima, Shigeru Inoue.
Travel medicine providers' opinions on the dengue vaccine TAK-003 as a travel vaccine and the need for decision-support information and materials before its launch in Japan.

Hum Vaccin Immunother. 21(1):2483560. 2025

DOI: [10.1080/21645515.2025.2483560](https://doi.org/10.1080/21645515.2025.2483560)

This work is licensed under [CC BY-NC 4.0](https://creativecommons.org/licenses/by-nc/4.0/)